To the best of our knowledge, this is the first study to report a relationship between a good clinical response to anti-TNF-α treatment and the plasma levels of KS, HA and HAPLN1 in JIA patients. The gene discussed is HAPLN1; the disease is juvenile idiopathic arthritis.